Determination of Selexipag in pharmaceutical tablets by high-performance liquid chromatography
Is this your thesis?
This record came from a bulk archive import. If it’s yours, link it to your profile.
Abstract (EN)
Selexipag is an oral prostacyclin IP receptor agonist that delays the progression of pulmonary arterial hypertension (PAH) and reduces hospitalization in patients in Class II and III according to the World Health Organization (WHO) functional classification. Selexipag is an oral prostacyclin IP receptor agonist that is structurally different from prostacyclin. In this thesis study, a new HPLC method was developed for the analysis of Selexipag from commercial pharmaceutical products. The mobile phase of the developed method is acetonitrile-water (40:60, v/v) mixture and buffered to pH 3. The flow rate and injection volume are 0.5 mL/min and 1.0 µL, respectively. Method validation was carried out according to the ICH Q2(R1) guideline and the results were evaluated statistically.
Author
Ebru Yıldız
How to Cite
Ebru Yıldız (Master Thesis). Determination of Selexipag in pharmaceutical tablets by high-performance liquid chromatography, 2024, Anadolu University.
Keywords
License
Tüm Hakları Saklıdır
This work is shared under the specified license terms.
More theses from Anadolu University
- Comparison of Koroglu operas by Uzeyir Hacibeyli and Ahmed Adnan Saygun(2024)
- Effects of manipulative news in social media on the Z generation(2023)
- Analysis of educational problems in guinea-bissau from independence to the present within the framework of public policy(2025)
- Yabancı dı̇l olarak Almanca, İngı̇lı̇zce ve Türkçe ders kı̇taplarında kültürlerarasılık konusu üzerı̇ne(2025)
- Representation of educational news in the media: A review of educational news in the context of critical discourse analysis(2024)
- Episkopeion building complex of Olympos Ancient City(2013)
